29.06.2006 15:20:00

Dendrite Appoints Carl L. Cohen as President of Marketing Solutions

Dendrite International, Inc. (NASDAQ:DRTE) a leadingprovider of pharmaceutical industry solutions, today announced theappointment of Carl L. Cohen as President of its Marketing Solutionsdivision. Mr. Cohen is an integral addition to Dendrite's newmanagement team and will be responsible for driving this rapidlygrowing division.

Mr. Cohen joins Dendrite from Starwood Hotels and ResortsWorldwide, one of the largest hotel chains in the world, where he mostrecently served as Senior Vice President. Mr. Cohen held severalstrategic positions during his tenure at Starwood, including runningits software and services division and starting a profitable broadbandbusiness unit. He also led many crucial initiatives, notably thecreation of a new reservation and loyalty marketing system for thehotel chain.

Previously, Mr. Cohen served as Chief Marketing Officer atWrenchhead.com and Executive Vice President of Marketing forChampionship Auto Racing Teams, a global brand in auto sports. Duringhis career, Mr. Cohen has held several senior marketing and brandmanagement leadership positions at companies such as Philip Morris,Colgate Palmolive and Reckitt & Coleman.

"Based on the products and services available today and thosecoming in the future, the Marketing Solutions division at Dendrite ispoised for explosive growth on a global scale," said Mr. Cohen. "Theopportunity to join Dendrite at this exciting time, to help lead thisinnovative division, was one that I could not resist."

"Carl will bring a fresh perspective to Dendrite from a successfulcareer that has spanned more than 20 years in a wide range ofindustries," said Joseph Ripp, president and COO of Dendrite. "We'relooking forward to Carl's contributions, including spearheading thekind of new thinking and approaches that will be instrumental toDendrite as we continue to forge a leadership path."

Mr. Cohen is a graduate of SUNY at Albany and earned his Master'sof Business Administration from The Wharton School of the Universityof Pennsylvania.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enablessales, marketing, clinical and compliance solutions for the globalpharmaceutical industry. The Company's clients are located in morethan 50 countries and include the world's top 20 pharmaceuticalcompanies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

This document may contain forward-looking statements that may beidentified by such forward-looking terminology as "expect," "believe,""anticipate," "will," "intend," "plan," "target," "outlook,""guidance," and similar statements or variations. Such forward-lookingstatements are based on our current expectations, estimates,assumptions and projections and involve significant risks anduncertainties, including risks which may result from our dependence onthe pharmaceutical industry; fluctuations in quarterly revenues due tolengthy sales and implementation cycles for certain of our solutions;our fixed expenses in relation to fluctuating revenues and variationsin customers' budget cycles; dependence on certain major customers;changes in demand for our products and services attributable to anyweakness experienced in the economy or mergers, acquisitions andconsolidations in the pharmaceutical industry; successful and timelydevelopment and introduction of new products and versions; rapidtechnological changes; increased competition; internationaloperations; integrating the entities we acquire; our ability toeffectively manage our growth; the protection of our proprietarytechnology; our ability to compete in the Internet-related productsand services market; the continued demand for Internet-relatedproducts and services; the ability of our third party vendors torespond to technological change; our ability to maintain ourrelationships with third-party vendors; less favorable thananticipated results from strategic relationships; dependence of datasolutions on strategic relationships; events which may affect the U.S.and world economies; and catastrophic events which could negativelyaffect our information technology infrastructure. Other importantfactors that should be reviewed and carefully considered are includedin the company's 10-K, 10-Qs, and other reports filed with the SEC.Actual results may differ materially. The company assumes noobligation for updating any such forward-looking statements to reflectactual results, changes in assumptions or other changes affecting suchforward-looking statements.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 523,40 -1,36%
S&P 600 SmallCap 935,46 -0,94%